Daré Bioscience to Participate in H.C. Wainwright Global Investment Conference
Ms. Johnson’s virtual fireside chat will be available on-demand at https://journey.ct.events/view/2fa53f81-bd7f-404e-ad1b-20ea02738d5b and under “Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.darebioscience.com, beginning at
Following the conclusion of the conference, an archived webcast of the fireside chat will be available on the company’s website until
About Daré Bioscience
Daré Bioscience is a biopharmaceutical company committed to advancing innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, and vaginal and sexual health.
Daré’s first FDA-approved product, XACIATO™ (clindamycin phosphate vaginal gel, 2%), is a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. XACIATO is a clear, colorless, viscous gel, to be administered once intravaginally as a single dose. Daré’s portfolio also includes potential first-in-category candidates in clinical development: Ovaprene®, a novel, hormone-free monthly contraceptive whose
Daré may announce material information about its finances, product and product candidates, clinical trials and other matters using the Investors section of its website (http://ir.darebioscience.com),
Investors on behalf of Daré
Media on behalf of Daré Bioscience, Inc.:
Source: Daré Bioscience, Inc.